Transformational cell therapies for patients with pancreatic disease

OUR PIPELINE OF CELL THERAPIES IS CHANGING THE OUTLOOK FOR PATIENTS WITH CHRONIC PANCREATITIS AND TYPE 1 DIABETES.

THE PROSPECTUS (COMPRISED OF THE REPLACEMENT PROSPECTUS WHICH IS TO BE READ IN CONJUNCTION WITH A SUPPLEMENTARY PROSPECTUS) IS AN IMPORTANT DOCUMENT THAT SHOULD BE READ IN ITS ENTIRETY. IF YOU HAVE ANY DOUBTS AS TO HOW TO DEAL WITH IT, YOU SHOULD CONSULT YOUR LEGAL, FINANCIAL OR OTHER PROFESSIONAL ADVISER. AN INVESTMENT IN SHARES OFFERED UNDER THIS PROSPECTUS IS HIGHLY SPECULATIVE. BY ACCESSING THE PROSPECTUS (BY CLICKING ON THE LINK BELOW) YOU ACKNOWLEDGE THAT YOU HAVE READ AND ACCEPT THE TERMS SET OUT IN THIS NOTICE.

THE REPLACEMENT PROSPECTUS DATED 25 FEBRUARY 2019 AND LODGED WITH ASIC BY KOLIGO THERAPEUTICS LIMITED (COMPANY) ON THAT DATE (REPLACEMENT PROSPECTUS) REPLACES THE ORIGINAL PROSPECTUS DATED 8 FEBRUARY 2019 (ORIGINAL PROSPECTUS) AND LODGED BY THE COMPANY WITH THE ASIC ON THAT DATE. THE COMPANY HAS LODGED A SUPPLEMENTARY PROSPECTUS WITH ASIC DATED 11 APRIL 2019 (SUPPLEMENTARY PROSPECTUS) WHICH MUST BE READ IN CONJUNCTION WITH THE REPLACEMENT PROSPECTUS (AND TOGETHER, ARE REFERRED AS THE PROSPECTUS).

THE PROSPECTUS IS FOR AN INITIAL PUBLIC OFFER OF 30,000,000 SHARES AT AN ISSUE PRICE OF $0.20 PER SHARE TO RAISE $6,000,000.

OVERSUBSCRIPTIONS OF UP TO A FURTHER 5,000,000 SHARES AT AN ISSUE PRICE OF $0.20 EACH TO RAISE UP TO AN ADDITIONAL $1,000,000 MAY BE ACCEPTED.

The Company has applied to ASX Limited (ASX) for admission to the official list of the ASX and quotation of its shares on ASX.

DISCLAIMER

Important Information

You must read this important notice before you attempt to access the electronic version of the Replacement Prospectus or the Supplementary Prospectus accessible through this website. The information on this page is not part of the Replacement Prospectus or the Supplementary Prospectus. If you do not understand it, you should consult your professional adviser without delay. This website is not intended for US persons.

Lodgement of this Replacement Prospectus and Supplementary Prospectus with ASIC

The paper form of the Replacement Prospectus and the Supplementary Prospectus available electronically through this website have been lodged with the Australian Securities and Investments Commission.

No offer of securities is made on the basis of the electronic version of the the Replacement Prospectus or the Supplementary Prospectus accessible through this website. An application for Shares can be made by either:

    • printing and completing the relevant Application Form attached to or accompanied by the electronic Supplementary Prospectus; or

 

  • completing the relevant Application Form attached to or accompanied by a paper form of the Supplementary Prospectus,

and then lodging the form and the application monies in accordance with the details set out in the Supplementary Prospectus and the relevant Application Form.

No Advice

Nothing contained on this website or in the Replacement Prospectus or the Supplementary Prospectus constitutes investment, legal, business, tax or other advice. In particular, the information on this website and in the Replacement Prospectus and the Supplementary Prospectus does not take into account your investment objectives, financial situation or particular needs. In making an investment decision, you must rely on your own examination of the Company and the securities and terms of the offering, including the merits and risks involved. You should consult your professional adviser for legal, business or tax advice.

Warning

For legal reasons, the electronic version of the Replacement Prospectus and the Supplementary Prospectus accessible through this website is available to persons accessing this website from within Australia only. If you are accessing this website from anywhere outside Australia, please do not download the electronic version of the Replacement Prospectus or the Supplementary Prospectus. In particular, the offering of securities of the Company under the Replacement Prospectus and the Supplementary Prospectus is not being made in the United States. The Replacement Prospectus and the Supplementary Prospectus must not be released or distributed in the United States or to, or for the account or benefit of, any person in the United States, or in any jurisdiction outside of Australia where distribution may be restricted by law. The Replacement Prospectus and the Supplementary Prospectus does not constitute an offer of securities in the United States or to, or for the account or benefit of, any person in the United States, or in any other jurisdiction where, or to any person to whom, it would not be lawful to issue the Replacement Prospectus and the Supplementary Prospectus or make the offer. The securities referred to in the Replacement Prospectus and the Supplementary Prospectus have not been and will not be registered under the U.S. Securities Act of 1933, as amended, or under the securities laws of any state or other jurisdiction of the United States. Any securities described in, or sold pursuant to, the Replacement Prospectus and the Supplementary Prospectus may not be offered or sold in the United States or to, or for the account or benefit of, any person in the United States absent registration under the Securities Act or pursuant to an applicable exemption from, or a transaction not subject to, such registration. It is the responsibility of any applicant outside Australia to ensure compliance with all laws of any country relevant to their applications, and any such applicant should consult their professional advisers as to whether any government or other consents are required, or whether any formalities need to be observed to enable them to apply for and be issued any securities. It is not practicable for the Company to comply generally with the securities laws of overseas jurisdictions having regard to the cost of complying with regulatory requirements in each relevant jurisdiction.

By proceeding, you acknowledge and agree to the above statements and that:

you are a resident of Australia accessing this website from Australia;

you are not in the United States or a person acting for the account or benefit of a person in the United States; and

you will not make a copy of the Information available to, or distribute a copy of the Information to, or for the account or benefit of, any person in the United States or any person in any other place in which, or to any other person to whom, it would be unlawful to do so.